Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Regeneron Pharmaceuticals : New Findings from Regeneron Pharmaceuticals Inc. in Gastrointestinal Hormones Provides New Insights (FGFR3-TACC3 fusion proteins act as naturally...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/23/2017 | 08:15pm CET

New Findings from Regeneron Pharmaceuticals Inc. in Gastrointestinal Hormones Provides New Insights (FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling)

By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Fresh data on Hormones - Gastrointestinal Hormones are presented in a new report. According to news reporting out of Tarrytown, New York, by NewsRx editors, research stated, "The epidermal growth factor receptor (EGFR) is a clinically validated target in head and neck squamous cell carcinoma (HNSCC), where EGFR-blocking antibodies are approved for first-line treatment. However, as with other targeted therapies, intrinsic/acquired resistance mechanisms limit efficacy."

Our news journalists obtained a quote from the research from Regeneron Pharmaceuticals Inc., "In the FaDu HNSCC xenograft model, we show that combined blockade of EGFR and ERBB3 promotes rapid tumor regression, followed by the eventual outgrowth of resistant cells. RNA sequencing revealed that resistant cells express FGFR3-TACC3 fusion proteins, which were validated as drivers of the resistant phenotype by several approaches, including CRISPR-mediated inactivation of FGFR3-TACC3 fusion genes. Interestingly, analysis of signaling in resistant cell lines demonstrated that FGFR3-TACC3 fusion proteins promote resistance by preferentially substituting for EGFR/RAS/ERK signaling rather than ERBB3/PI3K/AKT signaling. Furthermore, although FGFR3-TACC3 fusion proteins promote resistance of additional EGFR-dependent HNSCC and lung cancer cell lines to EGFR blockade, they are unable to compensate for inhibition of PI3K signaling in PIK3CA-mutant HNSCC cell lines. Validation of FGFR3-TACC3 fusion proteins as endogenous drivers of resistance in our screen provides strong evidence that these fusions are capable of substituting for EGFR signaling."

According to the news editors, the research concluded: "Thus, FGFR3-TACC3 fusion proteins may represent a novel mechanism of acquired resistance in EGFR-dependent cancers of multiple cell lineages."

For more information on this research see: FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling. Oncogene, 2017;36(4):471-481. Oncogene can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Oncogene - www.nature.com/onc/)

Our news journalists report that additional information may be obtained by contacting C. Daly, Regeneron Pharmaceut Inc, Tarrytown, NY 10591, United States. Additional authors for this research include C. Castanaro, W. Zhang, Q. Zhang, Y. Wei, M. Ni, T.M. Young, L. Zhang, E. Burova and G. Thurston (see also Hormones - Gastrointestinal Hormones).

Keywords for this news article include: Tarrytown, New York, United States, North and Central America, Intercellular Signaling Peptides and Proteins, Gastrointestinal Hormone Receptors, Receptor Protein-Tyrosine Kinases, Epidermal Growth Factor Receptor, Gastrointestinal Hormones, Epidermal Growth Factors, Growth Factor Receptors, Phosphotransferases, Membrane Proteins, Fusion Proteins, Protein Kinases, Amino Acids, Cell Line, Genetics, Regeneron Pharmaceuticals Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
08:15p REGENERON PHARMACEUTICALS : New Findings from Regeneron Pharmaceuticals Inc. in ..
08:04p REGENERON PHARMACEUTICALS : Teen Scientist Researches New Approach to Neurologic..
01:01a REGENERON PHARMACEUTICALS : U.K. Biobank, Regeneron and GSK Announce Largest Gen..
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
03/16 REGENERON PHARMACEUTICALS : Patent Issued for Genetically Modified Major Histoco..
03/16 REGENERON PHARMACEUTICALS : Researchers Submit Patent Application, "Humanized Il..
03/16 REGENERON PHARMACEUTICALS : and Sanofi to Present New Phase 3 Praluent® alirocum..
03/15 REGENERON PHARMACEUTICALS : Teen Scientist Researches New Approach to Neurologic..
03/15 REGENERON PHARMACEUTICALS : Teen Scientist Researches New Approach to Neurologic..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/21 Sanofi, Regeneron sue Amgen over eczema drug
03/21 AMERICAN COLLEGE OF CARDIOLOGY : No Repatha Of Glory
03/21 Aggressive Payers Block Access To PCSK9s
03/17 AMGEN TANKS ON REPATHA DATA : Analysis
03/13 Investors await details of Amgen's CVOT data for cholesterol med Repatha on F..
Advertisement
Financials ($)
Sales 2017 5 481 M
EBIT 2017 2 150 M
Net income 2017 1 011 M
Finance 2017 1 490 M
Yield 2017 -
P/E ratio 2017 43,31
P/E ratio 2018 33,78
EV / Sales 2017 6,87x
EV / Sales 2018 5,67x
Capitalization 39 159 M
More Financials
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 423 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
George Damis Yancopoulos President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Neil Stahl Executive VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..0.56%39 159
AMGEN, INC.14.53%123 319
CELGENE CORPORATION6.58%95 978
GILEAD SCIENCES, INC.-5.28%88 658
ACTELION LTD24.49%29 874
VERTEX PHARMACEUTICALS..22.22%22 369
More Results